Phase I/II, Open-Label Trial of Three Monoclonal Antibodies
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Monoclonal antibody infusions will prevent rebound of viremia in well-suppressed
HAART-treated individuals who began therapy during acute and early HIV-1 infection.